Corinne Savill
Corporate Officer/Principal at CULLINAN THERAPEUTICS, INC.
Net worth: 3 M $ as of 2024-03-30
Profile
Corinne Savill is currently the Chief Business Officer at Cullinan Oncology, Inc. She previously worked as the CEO of Imutran Ltd.
from 1995 to 2001, and as the Global Head of Business Development & Licensing at Novartis Pharma AG from 2002 to 2017.
She also briefly served as a Director at Cantargia AB in 2018.
Dr. Savill has an undergraduate degree from The University of Manchester and a doctorate from Middlesex School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-02-21 | 203,490 ( 0.47% ) | 3 M $ | 2024-03-30 |
Corinne Savill active positions
Companies | Position | Start |
---|---|---|
CULLINAN THERAPEUTICS, INC. | Corporate Officer/Principal | 2017-01-31 |
Former positions of Corinne Savill
Companies | Position | End |
---|---|---|
CANTARGIA AB | Director/Board Member | 2018-05-20 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 2017-01-31 |
Imutran Ltd. | Chief Executive Officer | 2000-12-31 |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Training of Corinne Savill
The University of Manchester | Undergraduate Degree |
Middlesex School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
CANTARGIA AB | Health Technology |
CULLINAN THERAPEUTICS, INC. | Health Technology |
Private companies | 4 |
---|---|
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
Imutran Ltd. |
- Stock Market
- Insiders
- Corinne Savill